Leveraging Adeno-Associated Viruses (AAVs) in therapeutic approaches for monogenic neurological diseases
Supplied by PerkinElmer on Wednesday, 07 September, 2022
Within the field of neurological diseases, there is great interest in looking at rare diseases of monogenic origin with the hope of developing disease-modifying gene therapies, as opposed to treatments for symptom management. Therefore, using relatively tunable systems like recombinant AAVs, scientists are also exploring in vivo gene delivery in parallel to ex vivo.
Learn about key strategies and innovations in this space that are enabling advanced gene therapy.
Related White Papers
A fully validated method to determine mycotoxins by Stable Isotope Dilution QSight LC/MS/MS
Examine a proven method for the analysis of 12...
Your guide to cell-based fluorescence assays
Learn how to master the challenges of cell-based fluorescence assays and improve the quality and...
Streamlined set-up and access to multiple read-out options with PROTAC assays
Latest PROTAC advances raise the bar for oncology...
